Show simple item record

dc.contributor.authorNadeeshani, Hen_NZ
dc.contributor.authorLi, Jen_NZ
dc.contributor.authorYing, Ten_NZ
dc.contributor.authorZhang, Ben_NZ
dc.contributor.authorLu, Jen_NZ
dc.date.accessioned2022-03-21T03:46:32Z
dc.date.available2022-03-21T03:46:32Z
dc.date.copyright2021en_NZ
dc.identifier.citationJournal of Advanced Research, 37 (2022), pp. 267–278.
dc.identifier.issn2090-1232en_NZ
dc.identifier.urihttp://hdl.handle.net/10292/15010
dc.description.abstractBackground Elderly population has been progressively rising in the world, thus the demand for anti-aging heath products to assure longevity as well as to ameliorate age-related complications is also on the rise. Among various anti-aging health products, nicotinamide mononucleotide (NMN) has been gaining attentions of the consumers and the scientific community. Aim of review This article intends to provide an overview on the current knowledge on promises and safety concerns of NMN as an anti-aging health product. Key scientific concepts of review Nicotinamide adenine dinucleotide (NAD+) levels in the body deplete with aging and it is associated with downregulation of energy production in mitochondria, oxidative stress, DNA damage, cognitive impairment and inflammatory conditions. However, NMN, as the precursor of NAD+, can slow down this process by elevating NAD+ levels in the body. A number of in vivo studies have indicated affirmative results of therapeutic effects for various age-induced complications with NMN supplementation. One preclinical and one clinical study have been conducted to investigate the safety concerns of NMN administration while a few more human clinical trials are being conducted. As there is a large influx of NMN based anti-aging products on the market, proper clinical investigations are urgently needed to find out the effectiveness and safety of NMN supplementation.
dc.languageenen_NZ
dc.publisherElsevier BVen_NZ
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S2090123221001491
dc.rights(C) 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
dc.subjectAge-induced diseases; Anti-aging; Nicotinamide adenine dinucleotide; Nicotinamide mononucleotide; Supplement
dc.titleNicotinamide Mononucleotide (NMN) as an Anti-aging Health Product – Promises and Safety Concernsen_NZ
dc.typeJournal Article
dc.rights.accessrightsOpenAccessen_NZ
dc.identifier.doi10.1016/j.jare.2021.08.003en_NZ
pubs.elements-id439338
aut.relation.journalJournal of Advanced Researchen_NZ


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record